| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiology, Interventional | 9 | 2024 | 138 | 3.380 |
Why?
|
| Radiography, Interventional | 9 | 2023 | 305 | 2.690 |
Why?
|
| Embolization, Therapeutic | 9 | 2021 | 551 | 2.030 |
Why?
|
| Molecular Imaging | 4 | 2014 | 185 | 1.550 |
Why?
|
| Liver Neoplasms | 13 | 2022 | 4557 | 1.340 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2020 | 85 | 1.300 |
Why?
|
| Medical Oncology | 5 | 2024 | 1423 | 1.140 |
Why?
|
| Catheterization | 7 | 2013 | 410 | 1.120 |
Why?
|
| Venous Thrombosis | 4 | 2023 | 384 | 1.080 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 348 | 1.070 |
Why?
|
| Quality Improvement | 3 | 2020 | 851 | 1.060 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2016 | 112 | 1.060 |
Why?
|
| Angiomyolipoma | 2 | 2016 | 31 | 1.050 |
Why?
|
| Drug Delivery Systems | 3 | 2023 | 669 | 1.040 |
Why?
|
| Image-Guided Biopsy | 5 | 2021 | 327 | 1.010 |
Why?
|
| Immunotherapy | 9 | 2024 | 3341 | 0.980 |
Why?
|
| Neoplasms | 10 | 2024 | 15193 | 0.950 |
Why?
|
| Endovascular Procedures | 4 | 2020 | 516 | 0.920 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2020 | 340 | 0.900 |
Why?
|
| Vena Cava Filters | 2 | 2020 | 88 | 0.890 |
Why?
|
| Population Health | 2 | 2020 | 51 | 0.880 |
Why?
|
| Venous Thromboembolism | 3 | 2023 | 335 | 0.870 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2022 | 2027 | 0.870 |
Why?
|
| Device Removal | 3 | 2020 | 337 | 0.860 |
Why?
|
| Kidney Neoplasms | 4 | 2024 | 3022 | 0.840 |
Why?
|
| Renal Dialysis | 3 | 2021 | 945 | 0.810 |
Why?
|
| Fractures, Compression | 1 | 2021 | 42 | 0.800 |
Why?
|
| Injections, Intralesional | 2 | 2021 | 164 | 0.780 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2018 | 592 | 0.780 |
Why?
|
| Uterine Artery Embolization | 1 | 2020 | 10 | 0.770 |
Why?
|
| Matrix Metalloproteinases | 2 | 2012 | 143 | 0.760 |
Why?
|
| Hypersplenism | 1 | 2020 | 23 | 0.760 |
Why?
|
| Uterine Myomectomy | 1 | 2020 | 14 | 0.750 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2020 | 27 | 0.750 |
Why?
|
| Spinal Fractures | 1 | 2021 | 132 | 0.750 |
Why?
|
| Spectroscopy, Near-Infrared | 3 | 2012 | 173 | 0.730 |
Why?
|
| Optical Imaging | 3 | 2020 | 157 | 0.710 |
Why?
|
| Leiomyoma | 1 | 2020 | 145 | 0.690 |
Why?
|
| Gastrostomy | 2 | 2021 | 180 | 0.660 |
Why?
|
| Catheter Ablation | 2 | 2021 | 620 | 0.660 |
Why?
|
| Colorectal Neoplasms | 7 | 2021 | 3578 | 0.640 |
Why?
|
| Liver Cirrhosis | 2 | 2022 | 941 | 0.590 |
Why?
|
| Ascites | 1 | 2017 | 198 | 0.590 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2016 | 9 | 0.580 |
Why?
|
| Biological Products | 1 | 2020 | 274 | 0.580 |
Why?
|
| Hysterectomy | 1 | 2020 | 611 | 0.580 |
Why?
|
| Hepatectomy | 3 | 2017 | 1011 | 0.580 |
Why?
|
| Hypertension, Portal | 1 | 2017 | 124 | 0.580 |
Why?
|
| Gelatin | 1 | 2016 | 49 | 0.570 |
Why?
|
| Acrylic Resins | 1 | 2016 | 43 | 0.570 |
Why?
|
| Spinal Neoplasms | 1 | 2021 | 631 | 0.560 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 118 | 0.560 |
Why?
|
| Humans | 68 | 2024 | 261506 | 0.560 |
Why?
|
| Biopsy, Needle | 1 | 2020 | 1363 | 0.560 |
Why?
|
| Uterine Neoplasms | 1 | 2020 | 545 | 0.550 |
Why?
|
| California | 3 | 2020 | 208 | 0.540 |
Why?
|
| Computer-Aided Design | 1 | 2016 | 73 | 0.540 |
Why?
|
| Vascular Closure Devices | 1 | 2015 | 11 | 0.520 |
Why?
|
| Microscopy, Fluorescence | 5 | 2020 | 769 | 0.520 |
Why?
|
| Treatment Outcome | 19 | 2022 | 32848 | 0.520 |
Why?
|
| Biomedical Research | 1 | 2022 | 806 | 0.520 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 846 | 0.520 |
Why?
|
| Patient Dropouts | 1 | 2015 | 88 | 0.510 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 136 | 0.510 |
Why?
|
| Wound Closure Techniques | 1 | 2015 | 28 | 0.510 |
Why?
|
| Vascular Grafting | 1 | 2015 | 50 | 0.510 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 129 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1303 | 0.490 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2024 | 2326 | 0.490 |
Why?
|
| Urinary Fistula | 1 | 2014 | 27 | 0.480 |
Why?
|
| Physicians | 1 | 2022 | 882 | 0.480 |
Why?
|
| Intestinal Fistula | 1 | 2014 | 44 | 0.480 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2016 | 255 | 0.470 |
Why?
|
| Catheterization, Central Venous | 1 | 2016 | 354 | 0.460 |
Why?
|
| Hemostatic Techniques | 1 | 2013 | 38 | 0.460 |
Why?
|
| Arteries | 1 | 2015 | 274 | 0.460 |
Why?
|
| Vascular Access Devices | 1 | 2013 | 51 | 0.460 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.450 |
Why?
|
| Prosthesis Design | 1 | 2016 | 749 | 0.450 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2014 | 196 | 0.440 |
Why?
|
| Cell Tracking | 1 | 2012 | 38 | 0.440 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 3821 | 0.420 |
Why?
|
| Cholangiocarcinoma | 4 | 2022 | 493 | 0.410 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2014 | 341 | 0.400 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 200 | 0.400 |
Why?
|
| Bile Duct Neoplasms | 3 | 2022 | 493 | 0.390 |
Why?
|
| Risk Factors | 9 | 2023 | 17523 | 0.390 |
Why?
|
| Precision Medicine | 3 | 2022 | 1154 | 0.380 |
Why?
|
| Florida | 2 | 2020 | 113 | 0.370 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2013 | 209 | 0.370 |
Why?
|
| Molecular Probe Techniques | 1 | 2010 | 46 | 0.370 |
Why?
|
| Image Enhancement | 1 | 2014 | 561 | 0.370 |
Why?
|
| 4-Chloro-7-nitrobenzofurazan | 1 | 2009 | 9 | 0.370 |
Why?
|
| Indicators and Reagents | 1 | 2009 | 128 | 0.360 |
Why?
|
| Deoxyglucose | 1 | 2009 | 115 | 0.350 |
Why?
|
| Aorta, Abdominal | 1 | 2010 | 152 | 0.350 |
Why?
|
| Liver Diseases | 1 | 2014 | 574 | 0.340 |
Why?
|
| Databases, Factual | 3 | 2020 | 2218 | 0.340 |
Why?
|
| Retrospective Studies | 16 | 2022 | 37905 | 0.340 |
Why?
|
| Hemorrhage | 1 | 2013 | 712 | 0.330 |
Why?
|
| Tumor Microenvironment | 6 | 2023 | 2864 | 0.330 |
Why?
|
| Algorithms | 4 | 2014 | 3890 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 960 | 0.330 |
Why?
|
| Postoperative Complications | 3 | 2020 | 5542 | 0.320 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2012 | 607 | 0.310 |
Why?
|
| Animals | 22 | 2023 | 59536 | 0.310 |
Why?
|
| Angiography | 5 | 2021 | 360 | 0.300 |
Why?
|
| Hyperthermia, Induced | 3 | 2023 | 510 | 0.300 |
Why?
|
| Microscopy, Confocal | 2 | 2020 | 663 | 0.290 |
Why?
|
| Liver Transplantation | 1 | 2015 | 1112 | 0.290 |
Why?
|
| Middle Aged | 20 | 2021 | 86204 | 0.290 |
Why?
|
| Aged | 17 | 2021 | 70117 | 0.280 |
Why?
|
| Female | 26 | 2021 | 141928 | 0.280 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 384 | 0.280 |
Why?
|
| Fluorescent Dyes | 4 | 2020 | 459 | 0.270 |
Why?
|
| Equipment Design | 4 | 2016 | 1204 | 0.270 |
Why?
|
| Biopsy | 1 | 2014 | 3443 | 0.270 |
Why?
|
| Blood Vessels | 1 | 2007 | 217 | 0.270 |
Why?
|
| Coloring Agents | 3 | 2016 | 234 | 0.270 |
Why?
|
| Indocyanine Green | 3 | 2016 | 117 | 0.270 |
Why?
|
| Chemoembolization, Therapeutic | 2 | 2017 | 181 | 0.270 |
Why?
|
| Intestinal Diseases | 1 | 2006 | 121 | 0.270 |
Why?
|
| Aorta | 1 | 2009 | 692 | 0.260 |
Why?
|
| Aneurysm, False | 2 | 2004 | 153 | 0.260 |
Why?
|
| Foreign Bodies | 1 | 2007 | 145 | 0.260 |
Why?
|
| Male | 20 | 2021 | 123000 | 0.250 |
Why?
|
| Mice | 14 | 2023 | 34495 | 0.250 |
Why?
|
| Endoscopy | 2 | 2007 | 479 | 0.250 |
Why?
|
| Patient Safety | 3 | 2021 | 649 | 0.240 |
Why?
|
| Pyrazoles | 1 | 2012 | 1471 | 0.230 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2292 | 0.230 |
Why?
|
| Quality of Life | 1 | 2017 | 4532 | 0.230 |
Why?
|
| Aneurysm, Infected | 1 | 2003 | 32 | 0.230 |
Why?
|
| Adult | 15 | 2021 | 77950 | 0.230 |
Why?
|
| Aneurysm, Ruptured | 1 | 2003 | 45 | 0.230 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.230 |
Why?
|
| Sulfonamides | 1 | 2012 | 1823 | 0.230 |
Why?
|
| HT29 Cells | 3 | 2013 | 159 | 0.220 |
Why?
|
| Financing, Organized | 1 | 2022 | 21 | 0.220 |
Why?
|
| Stents | 3 | 2021 | 1096 | 0.220 |
Why?
|
| Adolescent | 6 | 2020 | 31252 | 0.210 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 208 | 0.210 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 3719 | 0.210 |
Why?
|
| Immunologic Factors | 2 | 2023 | 649 | 0.210 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 821 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 4892 | 0.200 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2021 | 36 | 0.200 |
Why?
|
| Young Adult | 6 | 2021 | 21445 | 0.200 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 7222 | 0.200 |
Why?
|
| Research Personnel | 1 | 2022 | 156 | 0.200 |
Why?
|
| Mice, Nude | 4 | 2014 | 4307 | 0.190 |
Why?
|
| Splenic Artery | 1 | 2020 | 50 | 0.190 |
Why?
|
| Spine | 1 | 2021 | 293 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 29902 | 0.180 |
Why?
|
| Cryosurgery | 1 | 2021 | 167 | 0.180 |
Why?
|
| Hepatic Encephalopathy | 1 | 2020 | 66 | 0.180 |
Why?
|
| Nephritis, Interstitial | 1 | 2021 | 76 | 0.180 |
Why?
|
| Fluoroscopy | 2 | 2023 | 232 | 0.180 |
Why?
|
| Cost Savings | 1 | 2020 | 123 | 0.180 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2022 | 172 | 0.180 |
Why?
|
| Software | 1 | 2007 | 1321 | 0.180 |
Why?
|
| Herpesvirus 1, Human | 1 | 2020 | 113 | 0.180 |
Why?
|
| Ovarian Neoplasms | 2 | 2021 | 4638 | 0.180 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2022 | 223 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2021 | 327 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2003 | 499 | 0.170 |
Why?
|
| Platelet Count | 1 | 2020 | 490 | 0.170 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2020 | 169 | 0.170 |
Why?
|
| Immunomodulation | 1 | 2020 | 242 | 0.170 |
Why?
|
| Age Factors | 2 | 2020 | 5377 | 0.170 |
Why?
|
| CRISPR-Associated Proteins | 1 | 2018 | 7 | 0.170 |
Why?
|
| Particle Size | 2 | 2016 | 182 | 0.170 |
Why?
|
| Hospital Costs | 1 | 2020 | 228 | 0.170 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 368 | 0.160 |
Why?
|
| Interleukin-2 | 1 | 2022 | 842 | 0.160 |
Why?
|
| Biocompatible Materials | 1 | 2019 | 202 | 0.160 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2021 | 304 | 0.160 |
Why?
|
| Pathology, Surgical | 1 | 2018 | 81 | 0.160 |
Why?
|
| Electrocoagulation | 1 | 2018 | 65 | 0.160 |
Why?
|
| Bioengineering | 1 | 2018 | 27 | 0.160 |
Why?
|
| Reproducibility of Results | 4 | 2014 | 6009 | 0.160 |
Why?
|
| Lower Extremity | 1 | 2020 | 299 | 0.150 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2018 | 83 | 0.150 |
Why?
|
| CTLA-4 Antigen | 1 | 2021 | 657 | 0.150 |
Why?
|
| Musculoskeletal Diseases | 1 | 2018 | 81 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 14289 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2018 | 96 | 0.150 |
Why?
|
| Peptide Hydrolases | 2 | 2009 | 256 | 0.150 |
Why?
|
| Kidneys, Artificial | 1 | 2016 | 7 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 524 | 0.150 |
Why?
|
| Rats | 4 | 2021 | 6086 | 0.150 |
Why?
|
| Venous Insufficiency | 1 | 2017 | 38 | 0.150 |
Why?
|
| Collateral Circulation | 1 | 2016 | 59 | 0.150 |
Why?
|
| Cancer Vaccines | 1 | 2022 | 697 | 0.140 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 40 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 329 | 0.140 |
Why?
|
| Consensus | 1 | 2020 | 978 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 945 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2016 | 7551 | 0.140 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 486 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 9180 | 0.140 |
Why?
|
| Vascular Patency | 1 | 2016 | 218 | 0.140 |
Why?
|
| Gene Editing | 1 | 2018 | 216 | 0.140 |
Why?
|
| Regional Blood Flow | 1 | 2016 | 276 | 0.140 |
Why?
|
| Boston | 1 | 2015 | 108 | 0.130 |
Why?
|
| Telemedicine | 1 | 2021 | 471 | 0.130 |
Why?
|
| Brachial Artery | 1 | 2015 | 38 | 0.130 |
Why?
|
| Mesenteric Arteries | 2 | 2006 | 55 | 0.130 |
Why?
|
| Portal Vein | 1 | 2017 | 355 | 0.130 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 598 | 0.130 |
Why?
|
| Child | 5 | 2020 | 29154 | 0.130 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 323 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 1052 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2023 | 7702 | 0.130 |
Why?
|
| Odds Ratio | 1 | 2020 | 2316 | 0.130 |
Why?
|
| Popliteal Artery | 1 | 2015 | 52 | 0.130 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 475 | 0.130 |
Why?
|
| Models, Anatomic | 1 | 2016 | 154 | 0.130 |
Why?
|
| Axillary Artery | 1 | 2015 | 33 | 0.130 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 202 | 0.130 |
Why?
|
| Equipment Failure | 1 | 2015 | 191 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 2063 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 1586 | 0.130 |
Why?
|
| Genes, ras | 1 | 2018 | 667 | 0.130 |
Why?
|
| Peptides | 1 | 2021 | 1479 | 0.130 |
Why?
|
| Metastasectomy | 1 | 2016 | 200 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.120 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.120 |
Why?
|
| Comorbidity | 1 | 2020 | 2352 | 0.120 |
Why?
|
| Length of Stay | 1 | 2020 | 1900 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2015 | 263 | 0.120 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 1162 | 0.120 |
Why?
|
| Punctures | 1 | 2013 | 104 | 0.110 |
Why?
|
| ras Proteins | 1 | 2017 | 770 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2016 | 412 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 891 | 0.110 |
Why?
|
| Career Choice | 1 | 2015 | 232 | 0.110 |
Why?
|
| Neutrophils | 1 | 2017 | 835 | 0.110 |
Why?
|
| Palliative Care | 2 | 2021 | 2037 | 0.110 |
Why?
|
| Permeability | 1 | 2013 | 167 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2015 | 191 | 0.110 |
Why?
|
| Carcinoma, Lobular | 1 | 2016 | 611 | 0.110 |
Why?
|
| Magnetite Nanoparticles | 1 | 2013 | 50 | 0.110 |
Why?
|
| Infant | 3 | 2020 | 13310 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 328 | 0.110 |
Why?
|
| Celecoxib | 1 | 2012 | 200 | 0.110 |
Why?
|
| Medicare | 1 | 2017 | 860 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2023 | 1797 | 0.110 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 585 | 0.110 |
Why?
|
| Recurrence | 1 | 2020 | 4758 | 0.100 |
Why?
|
| Biological Transport | 1 | 2013 | 597 | 0.100 |
Why?
|
| Drainage | 1 | 2014 | 416 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 875 | 0.100 |
Why?
|
| Health Care Costs | 1 | 2016 | 674 | 0.100 |
Why?
|
| Radiographic Image Enhancement | 1 | 2014 | 402 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 4971 | 0.100 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 480 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 655 | 0.100 |
Why?
|
| Calcium Chloride | 1 | 2010 | 23 | 0.090 |
Why?
|
| Radiography | 2 | 2023 | 1904 | 0.090 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 2370 | 0.090 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2010 | 57 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2016 | 1987 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 3251 | 0.090 |
Why?
|
| Survival Rate | 4 | 2021 | 12221 | 0.090 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2022 | 334 | 0.090 |
Why?
|
| United States | 3 | 2022 | 15433 | 0.090 |
Why?
|
| Glioma | 1 | 2021 | 1963 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 1 | 2012 | 483 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2022 | 5112 | 0.090 |
Why?
|
| Students, Medical | 1 | 2015 | 399 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2055 | 0.090 |
Why?
|
| Doxycycline | 1 | 2010 | 178 | 0.090 |
Why?
|
| Mutation | 3 | 2018 | 15179 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 705 | 0.090 |
Why?
|
| Nephrectomy | 1 | 2014 | 779 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1202 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2010 | 210 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2010 | 429 | 0.080 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2020 | 16273 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4320 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 8865 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2014 | 1271 | 0.080 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2007 | 33 | 0.080 |
Why?
|
| Endoscopes | 1 | 2007 | 43 | 0.080 |
Why?
|
| Prevalence | 1 | 2015 | 3260 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 14551 | 0.080 |
Why?
|
| Contrast Media | 1 | 2014 | 1472 | 0.070 |
Why?
|
| Fluorescence | 1 | 2007 | 195 | 0.070 |
Why?
|
| Peritoneum | 1 | 2007 | 150 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 521 | 0.070 |
Why?
|
| Light | 1 | 2007 | 245 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2508 | 0.070 |
Why?
|
| Prognosis | 4 | 2017 | 21713 | 0.070 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 671 | 0.070 |
Why?
|
| Optics and Photonics | 1 | 2007 | 146 | 0.070 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2314 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.060 |
Why?
|
| Melanoma | 1 | 2022 | 5317 | 0.060 |
Why?
|
| Mice, Transgenic | 1 | 2012 | 4143 | 0.060 |
Why?
|
| DNA | 1 | 2013 | 2693 | 0.060 |
Why?
|
| Rectum | 1 | 2006 | 467 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2021 | 4654 | 0.060 |
Why?
|
| Celiac Artery | 1 | 2004 | 40 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 6682 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 1226 | 0.060 |
Why?
|
| Seizures | 1 | 2009 | 989 | 0.060 |
Why?
|
| Glucose | 1 | 2009 | 1248 | 0.060 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2023 | 208 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2013 | 6869 | 0.050 |
Why?
|
| Mitotane | 1 | 2022 | 39 | 0.050 |
Why?
|
| Cytokines | 2 | 2022 | 2809 | 0.050 |
Why?
|
| Steel | 1 | 2021 | 10 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 310 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 96 | 0.050 |
Why?
|
| Decompression | 1 | 2021 | 12 | 0.050 |
Why?
|
| Pancreatitis | 1 | 2004 | 267 | 0.050 |
Why?
|
| Rats, Inbred BUF | 1 | 2021 | 26 | 0.050 |
Why?
|
| Acute Disease | 1 | 2006 | 2422 | 0.050 |
Why?
|
| Yttrium Radioisotopes | 1 | 2022 | 178 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2021 | 70 | 0.050 |
Why?
|
| Heparin | 1 | 2023 | 360 | 0.050 |
Why?
|
| Platelet Aggregation | 1 | 2021 | 257 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 2173 | 0.050 |
Why?
|
| Infliximab | 1 | 2021 | 130 | 0.050 |
Why?
|
| Hydrogels | 1 | 2021 | 123 | 0.050 |
Why?
|
| Catheters | 1 | 2021 | 126 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5159 | 0.050 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2021 | 202 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 2018 | 1910 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 14889 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2014 | 12873 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 234 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 644 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5178 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2023 | 550 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 134 | 0.040 |
Why?
|
| Microspheres | 1 | 2019 | 210 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2022 | 657 | 0.040 |
Why?
|
| Metals | 1 | 2019 | 155 | 0.040 |
Why?
|
| Musculoskeletal System | 1 | 2018 | 35 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2023 | 1529 | 0.040 |
Why?
|
| Polymers | 1 | 2019 | 223 | 0.040 |
Why?
|
| Diffusion of Innovation | 1 | 2018 | 160 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2022 | 840 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2016 | 173 | 0.040 |
Why?
|
| Dissection | 1 | 2016 | 156 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2022 | 899 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 285 | 0.030 |
Why?
|
| Brain | 1 | 2009 | 4113 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 694 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2021 | 1048 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Comprehension | 1 | 2015 | 120 | 0.030 |
Why?
|
| Awareness | 1 | 2015 | 126 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 1439 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2020 | 3033 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 500 | 0.030 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 29 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2022 | 1946 | 0.030 |
Why?
|
| Organic Chemicals | 1 | 2013 | 113 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 5767 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 1559 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 3570 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 15694 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2013 | 137 | 0.030 |
Why?
|
| Kidney | 1 | 2021 | 2146 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 1819 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 5047 | 0.020 |
Why?
|
| DNA Damage | 1 | 2018 | 1954 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2330 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2021 | 2819 | 0.020 |
Why?
|
| Registries | 1 | 2018 | 2170 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 6942 | 0.020 |
Why?
|
| Curriculum | 1 | 2015 | 860 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 4988 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 4298 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2171 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6207 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 1225 | 0.020 |
Why?
|
| Computer Systems | 1 | 2007 | 106 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 4053 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 329 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10331 | 0.010 |
Why?
|